Nanjing Medical To Build Health Care Industrial Park
This article was originally published in PharmAsia News
Executive Summary
Nanjing Medical Company has signed a 20-year real estate and land lease with Nanjing Compressor Co., Ltd. According to the contract, Nanjing Compressor will lease its number one production zone including all buildings, auxiliary equipment, facilities, fittings and land to Nanjing Medical at a total of 229.19 million yuan for the next 20 years. Nanjing Medical is to put in 5.5 million yuan for 55 percent equity of a new management company, which will be set up to oversee construction of the industrial park. With its focus on integrating logistics resources, Nanjing Medical is looking for investors to develop the municipal park into a center for high-end preventive medicine, health care and rehabilitation, business, product R&D and modern logistics. (Click here for more - Chinese Language)
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.